Double-edge Role of B Cells in Tumor Immunity: Potential Molecular Mechanism

Abstract

B cells are a heterogeneous population, which have distinct functions of antigen presentation, activating T cells, and secreting antibodies, cytokines as well as protease. It is supposed that the balance among these B cells subpopulation (resting B cells, activated B cells, Bregs, and other differentiated B cells) will determine the ultimate role of B cells in tumor immunity. There has been increasing evidence supporting opposite roles of B cells in tumor immunity, though there are no general acceptable phenotypes for them. Recent years, a new designated subset of B cells identified as Bregs has emerged from immunosuppressive and/or regulatory functions in tumor immune responses. Therefore, transferring activated B cells would be possible to become a promising strategy against tumor via conquering the immunosuppressive status of B cells in future. Understanding the potential mechanism of double-edge role of B cells will help researchers utilize activated B cells to improve their anti-tumor response. Moreover, the molecular pathways related to B cell differentiation are involved in its tumor-promoting effect, such as NF-κB, STAT3, BTK. So, we review the molecular and signaling pathway mechanisms of B cells involved in both tumor-promoting and tumor-suppressive immunity, in order to help researchers optimize B cells to fight cancer better.

Keywords

B cells / tumor immunity

References

[1] HuX, ZhangJ, WangJ, et al.. Landscape of B cell immunity and related immune evasion in human cancers. Nat Genet, 2019, 51(3): 560-567

[2] TokunagaR, NaseemM, LoJH, et al.. B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev, 2019, 73: 10-19

[3] BonizziG, KarinM. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol, 2004, 25(6): 280-288

[4] SunSC. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat Rev Immunol, 2017, 17(9): 545-558

[5] AmmiranteM, LuoJL, GrivennikovS, et al.. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature, 2010, 464(7286): 302-305

[6] AmmiranteM, KuraishyAI, ShalapourS, et al.. An IKKalpha-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev, 2013, 27(13): 1435-1440

[7] Wuerzberger-DavisSM, ChenY, YangDT, et al.. Nuclear export of the NF-kappaB inhibitor IkappaBalpha is required for proper B cell and secondary lymphoid tissue formation. Immunity, 2011, 34(2): 188-200

[8] HuynhJ, EtemadiN, HollandeF, et al.. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies. Semin Cancer Biol, 2017, 45: 13-22

[9] YangC, LeeH, PalS, et al.. B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS One, 2013, 8(5): e64159

[10] ZhangC, XinH, ZhangW, et al.. CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity, 2016, 44(4): 913-923

[11] RenY, YuK, SunS, et al.. JSI124 inhibits breast cancer cell growth by suppressing the function of B cells via the downregulation of signal transducer and activator of transcription 3. Oncol Lett, 2014, 8(2): 928-932

[12] OlkhanudPB, DamdinsurenB, BodogaiM, et al.. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res, 2011, 71(10): 3505-3515

[13] Lee-ChangC, BodogaiM, Martin-MontalvoA, et al.. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. J Immunol, 2013, 191(8): 4141-4151

[14] GundersonAJ, KanedaMM, TsujikawaT, et al.. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov, 2016, 6(3): 270-285

[15] SeilerT, DreylingM. Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives. Expert Opin Investig Drugs, 2017, 26(8): 909-915

[16] HamzeM, DesmetzC, GuglielmiP. B cell-derived cytokines in disease. Eur Cytokine Netw, 2013, 24(1): 20-26

[17] SchioppaT, MooreR, ThompsonRG, et al.. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci USA, 2011, 108(26): 10 662-10 667

[18] InoueS, LeitnerWW, GoldingB, et al.. Inhibitory effects of B cells on antitumor immunity. Cancer Res, 2006, 66(15): 7741-7747

[19] TaoH, LuL, XiaY, et al.. Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10. Eur J Immunol, 2015, 45(4): 999-1009

[20] HorikawaM, Minard-ColinV, MatsushitaT, et al.. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. J Clin Invest, 2011, 121(11): 4268-4280

[21] Gorosito SerranM, Fiocca VernengoF, BeccariaCG, et al.. The regulatory role of B cells in autoimmunity, infections and cancer: Perspectives beyond IL10 production. FEBS Lett, 2015, 589(22): 3362-3369

[22] Pylayeva-GuptaY, DasS, HandlerJS, et al.. IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. Cancer Discov, 2016, 6(3): 247-255

[23] OuZ, WangY, LiuL, et al.. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals. Oncotarget, 2015, 6(28): 26 065-26 078

[24] LeeKE, SpataM, BayneLJ, et al.. Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. Cancer Discov, 2016, 6(3): 256-269

[25] Seton-RogersS. Pancreatic cancer: Spotlight on B cells. Nat Rev Cancer, 2016, 16(2): 67

[26] ForteG, SorrentinoR, MontinaroA, et al.. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol, 2012, 189(5): 2226-2233

[27] KempTJ, MooreJM, GriffithTS. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol, 2004, 173(2): 892-899

[28] IglesiaMD, VincentBG, ParkerJS, et al.. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res, 2014, 20(14): 3818-3829

[29] TadmorT, ZhangY, ChoHM, et al.. The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol Immunother, 2011, 60(5): 609-619

[30] ZhangY, EliavY, ShinSU, et al.. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol Immunother, 2013, 62(1): 87-99

[31] ShahS, DivekarAA, HilcheySP, et al.. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer, 2005, 117(4): 574-586

[32] GuyTV, TerryAM, BoltonHA, et al.. Pro- and anti-tumour effects of B cells and antibodies in cancer: a comparison of clinical studies and preclinical models. Cancer Immunol Immunother, 2016, 65(8): 885-896

[33] KimSJ, CatonM, WangC, et al.. Increased IL-12 inhibits B cells’ differentiation to germinal center cells and promotes differentiation to short-lived plasmablasts. J Exp Med, 2008, 205(10): 2437-2448

[34] XiaY, TaoH, HuY, et al.. IL-2 augments the therapeutic efficacy of adoptively transferred B cells which directly kill tumor cells via the CXCR4/CXCL12 and perforin pathways. Oncotarget, 2016, 7(37): 60 461-60 474

[35] LiQ, LaoX, PanQ, et al.. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res, 2011, 17(15): 4987-4995

[36] LiQ, GroverAC, DonaldEJ, et al.. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells. J Immunol, 2005, 175(3): 1424-1432

[37] LiQ, Teitz-TennenbaumS, DonaldEJ, et al.. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol, 2009, 183(5): 3195-3203

[38] DiLilloDJ, YanabaK, TedderTF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol, 2010, 184(7): 4006-4016

[39] KimS, FridlenderZG, DunnR, et al.. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother, 2008, 31(5): 446-457

[40] SchwartzM, ZhangY, RosenblattJD. B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer, 2016, 4: 40

[41] SarvariaA, MadrigalJA, SaudemontA. B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol, 2017, 14(8): 662-674

[42] HagnM, JahrsdorferB. Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway. Oncoimmunology, 2012, 1(8): 1368-1375

[43] BaoY, CaoX. The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review. J Autoimmun, 2014, 55: 10-23

[44] WennholdK, WeberTM, Klein-GonzalezN, et al.. CD40-activated B cells induce anti-tumor immunity in vivo. Oncotarget, 2017, 8(17): 27 740-27 753

[45] Shimabukuro-VornhagenA, SchlosserHA, GryschokL, et al.. Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget, 2014, 5(13): 4651-4664

[46] WangJZ, ZhangYH, GuoXH, et al.. The double-edge role of B cells in mediating antitumor T-cell immunity: Pharmacological strategies for cancer immunotherapy. Int Immunopharmacol, 2016, 36: 73-85

[47] ShalapourS, Font-BurgadaJ, Di CaroG, et al.. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature, 2015, 521(7550): 94-98